UGT1A1 genotype does not affect tyrosine kinase inhibitors efficacy and safety in chronic myeloid leukemia

被引：4
|
作者：
Iurlo, Alessandra [1 ]
Bucelli, Cristina [1 ]
Cattaneo, Daniele [1 ]
Levati, Giorgia Virginia [1 ]
Viani, Benedetta [1 ]
Tavazzi, Dario [2 ,3 ]
Consonni, Dario [4 ]
Baldini, Luca [1 ]
Cappellini, Maria Domenica [2 ,3 ]
机构：
[1] Univ Milan, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Hematol Div, Milan, Italy
[2] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy
[3] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy
[4] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Epidemiol Unit, Milan, Italy
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2019年 / 94卷 / 11期
关键词：
RECOMMENDATIONS; CHEMOTHERAPY; MANAGEMENT; NILOTINIB;
D O I：
10.1002/ajh.25596
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E283 / E285
页数：3
相关论文
共 50 条
  • [1] HOW UGT1A1 GENOTYPE IMPACTS ON TKI EFFICACY AND SAFETY IN CHRONIC MYELOID LEUKEMIA PATIENTS
    Iurlo, A.
    Bucelli, C.
    Cattaneo, D.
    Levati, G.
    Tavazzi, D.
    Consonni, D.
    Baldini, L.
    Cappellini, M. D.
    HAEMATOLOGICA, 2019, 104 : 143 - 144
  • [2] Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety
    Garcia-Gutierrez, Valentin
    Carlos Hernandez-Boluda, Juan
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [3] Tyrosine kinase inhibitors are potent and selective inhibitors of UGT1A1: Tools for UGT phenotyping
    Kalyanaraman, Nataraj
    Li, Chun
    Surapaneni, Sekhar S.
    Kumar, Gondi N.
    DRUG METABOLISM REVIEWS, 2006, 38 : 43 - 43
  • [4] Novel tyrosine-kinase inhibitors for the treatment of chronic myeloid leukemia: safety and efficacy
    Massaro, Fulvio
    Colafigli, Gioia
    Molica, Matteo
    Breccia, Massimo
    EXPERT REVIEW OF HEMATOLOGY, 2018, 11 (04) : 301 - 306
  • [5] A safety review of tyrosine kinase inhibitors for chronic myeloid leukemia
    Ozmen, Deniz
    Alpaydin, Duygu Demet
    Saldogan, Muhammed Ali
    Eskazan, Ahmet Emre
    EXPERT OPINION ON DRUG SAFETY, 2024, 23 (04) : 411 - 423
  • [6] Efficacy and safety of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: a meta-analysis
    Xie, Bingqian
    Gao, Minjie
    Hu, Liangning
    Kong, Yuanyuan
    Gao, Lu
    Wang, Houcai
    Yang, Guang
    Zhang, Yiwen
    Tao, Yi
    Xu, Hongwei
    Zhan, Fenghuang
    Wu, Xiaosong
    Shi, Jumei
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (02): : 1815 - 1821
  • [7] ASSESSMENT OF EFFICACY OF TYROSINE KINASE INHIBITORS IN TREATMENT OF CHRONIC MYELOID LEUKEMIA
    Yadrikhinskaya, V. N.
    Mulina, I. I.
    Sannikova, A. N.
    Palshina, A. M.
    Sleptsova, S. S.
    Aleksandrova, T. N.
    YAKUT MEDICAL JOURNAL, 2016, (04): : 30 - 33
  • [8] Tyrosine kinase inhibitors in chronic myeloid leukemia
    Sawyers, CL
    Druker, B
    CANCER JOURNAL FROM SCIENTIFIC AMERICAN, 1999, 5 (02): : 63 - 69
  • [9] Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors
    Kim, Sung-Hyun
    Menon, Hari
    Jootar, Saengsuree
    Saikia, Tapan
    Kwak, Jae-Yong
    Sohn, Sang-Kyun
    Park, Joon Seong
    Jeong, Seong Hyun
    Kim, Hyeoung Joon
    Kim, Yeo-Kyeoung
    Oh, Suk Joong
    Kim, Hawk
    Zang, Dae Young
    Chung, Joo Seop
    Shin, Ho Jin
    Do, Young Rok
    Kim, Jeong-A
    Kim, Dae-Young
    Choi, Chul Won
    Park, Sahee
    Park, Hye Lin
    Lee, Gong Yeal
    Cho, Dae Jin
    Shin, Jae Soo
    Kim, Dong-Wook
    HAEMATOLOGICA, 2014, 99 (07) : 1191 - 1196
  • [10] Efficacy of tyrosine kinase inhibitors on a mouse chronic myeloid leukemia model and chronic myeloid leukemia stem cells
    Tanaka, Yosuke
    Fukushima, Tsuyoshi
    Mikami, Keiko
    Adachi, Keito
    Fukuyama, Tomofusa
    Goyama, Susumu
    Kitamura, Toshio
    EXPERIMENTAL HEMATOLOGY, 2020, 90 : 46 - +
12345